Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page
- Check4 days agoChange DetectedFooter revision tag updated from Revision: v3.3.3 to Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe Study Locations section was updated: new sites were added across several U.S. states and international locations (e.g., Alabama, Arkansas, California, Colorado, Florida, Missouri, Ohio, Tennessee, Texas, Virginia, Tel Aviv, Chiba, Tokyo, Gyeonggido, Seoul Teugbyeolsi), and several existing sites were removed.SummaryDifference2%

- Check48 days agoChange DetectedA minor revision update indicates version v3.3.2 was published; no changes to core study content, eligibility, outcomes, or locations are evident in the visible page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page now displays Revision: v3.3.1, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded Tainan, Taiwan, 704 to the Locations section. Replaced the listing 'Tainan City, Taiwan, 704' with 'Tainan, Taiwan, 704' to reflect corrected locality naming.SummaryDifference0.4%

- Check76 days agoChange DetectedNo substantive content changes detected on the Study Details page; updates appear to be UI/formatting adjustments without changes to core sections such as eligibility criteria or outcome measures — To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.